Cannabis finds its way into treatment of Crohn s disease
|
|
- Oswald Lawrence
- 5 years ago
- Views:
Transcription
1 Europe PMC Funders Group Author Manuscript Published in final edited form as: Pharmacology ; 93(0): 1 3. doi: / Cannabis finds its way into treatment of Crohn s disease Rudolf Schicho 1 and Martin Storr 2 1 Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria 2 Department of Medicine II, Klinikum Großhadern, Ludwig-Maximilians University, Munich, Germany Keywords Inflammatory bowel disease; cannabinoids; prospective study In ancient medicine, Cannabis has been widely used to cure disturbances and inflammation of the bowel. A recent clinical study now shows that the medicinal plant Cannabis sativa has kept its expectancies proving to be highly efficient in cases of inflammatory bowel diseases (IBD). In a prospective placebo-controled study, Naftali and coworkers (Clin. Gastroenterol. Hepatol. 11, e1., 2013) have shown what has been largely anticipated from anectodal reports, that Cannabis produces significant clinical benefits in patients with Crohn s disease. The mechanisms involved are not clear yet but most likely include peripheral actions on cannabinoid receptors 1 and 2, and may also include central actions. The past ten years have seen a constant rise in publications dealing with the antiinflammatory effects of cannabinoids and the potential underlying mechanisms. Preclinical data on the ameliorationg effect of synthetic and natural cannabinoids in animal models mimicking features of inflammatory bowel disease (IBD) have been rapidly evolving. The reasonable idea that cannabinoids would be also beneficial in IBD patients was mainly based on results from experiments in cannabinoid receptor knock out mice and on data using cannabinoid receptor agonists and antagonists. Following a previous publication of a retrospective, observational study by Naftali et al. [1] and a questionaire performed by a different group in patients with ulcerative colitis (UC) and Crohn s disease (CD) [2], both revealing symptom relief and improvement after use of Cannabis, Naftali et al. have now presented a placebo controled prospective study in 21 patients with CD unresponsive to standard IBD treatment [3]. Although the primary endpoint of induction of remission was statistically not achieved, they were able to demonstrate that an 8-week treatment with THC-rich Cannabis caused a decrease of the Crohn s disease activity index (CDAI) in 90% of patients without producing significant side effects. The authors rightfully concluded that a larger patient group is warranted for future studies. Correspondence Rudolf Schicho, PhD Medical University of Graz Institute of Experimental and Clinical Pharmacology Universitätsplatz Graz Austria Phone: Fax: rudolf.schicho@medunigraz.at. The authors declare no conflict of interest.
2 Schicho and Storr Page 2 This is the first clinical trial on the effect of Cannabis in IBD and it confirms what has been suggested for a long time from experimental studies, namely that cannabinoids may provide antiinflammatory effects and symptomatic benefit in patients with IBD. The physiological fundament for the beneficial effects of Cannabis has been established a while ago and unraveled since then. The discovery of cannabinoid receptors and endogenous molecules activating these receptors led to the description of a coordinated network that is inherent to the mammalian organism, the so-called endocannabinoid system. This system consists of the canonical CB receptors (cannabinoid receptor 1 and 2; CB 1, CB 2 ), their endogeneous ligands anandamide and 2-arachidonoyl glycerol (2-AG), also called endocannabinoids, and their synthesizing and degrading enzymes. What capsaicin, the pungent ingredient of chili, is for vanilloid receptors and morphin for opioid receptors, is tetrahydrocannabinol (THC), the psychodelic ingredient of Cannabis, for cannabinoid (CB) receptors: the predominant herbal ligand. Thus, THC mimics the actions of anandamide and 2-AG. The wall of the gastrointestinal tract houses all components of the endocannabinoid system. Recent data show that these components are differentially expressed in human IBD indicating a regulatory role in the disease progress [4]. While anandamide and its synthesizing enzyme display lower levels in UC, expression of CB 2 receptors and of enzymes responsible for synthesis and degradation of 2-AG were increased [5]. The findings indicate that the CB 2 receptor plays a key role in the ameliorating effect of cannabinoids in IBD. The precise mechanism as to how cannabinoids contribute to improvement of IBD, however, is not clear but by use of experimental models of intestinal inflammation we are able to define a picture on how and at which targets cannabinoids cause improvement of inflammation. CB 1 and CB 2 receptors are located at the colonic epithelium and a protective effect of THC via epithelial permeability is conceivable (Fig. 1). Therefore, cannabinoids could enhance epithelial wound closure in the colon [6]. One of the prominent features of cannabinoids in experimental intestinal inflammation are their effects on immunocytes which mainly express CB 2 receptors. Upon CB 2 activation, T-cells undergo apoptosis and decreased proliferation in colitis [7]. Additionally, activation of CB 2 diminishes the recruitment of neutrophils, T- cells and macrophages to the inflamed colon [7]. CB receptors are also found in the enteric nervous system (ENS), which controls gut motility and secretion [8]. CB 1 receptors present in the ENS represent a break that protects the ENS from hyperstimulation, a situation easily caused by overexpression of inflammatory mediators that activate the ENS during IBD. Activation of CB receptors by THC, therefore, may reduce hypermotility associated with the inflammation of the gut [9]. The reduction of hypermotility may consequently alleviate diarrhea producing beneficial effects for the patient. It should be emphasized that the brain is the major site of CB 1 expression and that presence of CB 2 has been also detected in the brainstem [8]. The use of Cannabis in improving inflammation could therefore well include central effects, such as a reduction in pain sensation and relief of nausea and feeling of unpleasantness. One report suggests that a full antiinflammatory response of cannabinoids in gut inflammation includes the central nervous system since a peripherally restricted CB 1 /CB 2 receptor agonist was either not effective or too weak to improve colitis, depending on the exprimental model used [10].
3 Schicho and Storr Page 3 Acknowledgments References In their prospective study, Naftali et al. used THC-free Cannabis as placebo with no other cannabinoids present [3]. However, we should consider that also other ingredients of Cannabis, such as cannabidiol, cannabigerol, and tetrahydrocannabivarine (THCV), all of them non-psychotropic components of Cannabis, have proven antiinflammatory effects in experimental intestinal inflammation [9]. Their actions partly involve non-cb receptor mechanisms via, for instance, peroxisome proliferator-activated receptors (PPAR) and transient receptor potential cation channels subfamily V receptors (TRPV) and should be regarded as additive beneficial effects of Cannabis in the improvement of colitis in addition to THC-mediated effects. In summary, in agreement with the ancient use of Cannabis in intestinal disturbances and one decade of animal research, Cannabis was shown in a clinical trial to reduce symptoms in patients with CD. This elegant translation should be followed by larger trials confirming these results and by trials establishing the involved mechanisms to open a promising direction for future treatment of IBD. RS is supported by grants from the Austrian Science Fund (FWF P and P 25633). MS is supported by the Deutsche Forschungsgemeinschaft (DFG). [1]. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn s disease with cannabis: an observational study. Isr Med Assoc J. 2011; 13: [PubMed: ] [2]. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011; 23: [PubMed: ] [3]. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn s disease: a prospective placebocontrolled study. Clin Gastroenterol Hepatol. 2013; 11: e1. [PubMed: ] [4]. Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, Astarita G, Vanoli A, Dainese E, Guerci M, Piomelli D, Pender SL, MacDonald TT, Maccarrone M, Corazza GR. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 2011; 4: [PubMed: ] [5]. Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009; 4:e6893. [PubMed: ] [6]. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005; 129: [PubMed: ] [7]. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB 2 ) agonist ameliorates colitis in IL-10( / ) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012; 258: [PubMed: ] [8]. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010; 126: [PubMed: ] [9]. Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012; 18: [PubMed: ] [10]. Cluny NL, Keenan CM, Duncan M, Fox A, Lutz B, Sharkey KA. Naphthalen-1-yl-(4- pentyloxynaphthalen-1-yl) methanone (SAB378), a peripherally restricted cannabinoid CB 1 /CB 2
4 Schicho and Storr Page 4 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther. 2010; 334: [PubMed: ]
5 Schicho and Storr Page 5 Fig. 1. Potential targets and mechanisms of cannabinoids involved in the improvement of inflammatory bowel diseases (IBD) Natural and synthetic cannabinoids act via intestinal cannabinoid receptors 1 and 2 to regulate epithelial permeability, motility, secretion (via enteric nervous system), as well as leukocyte migration, recruitment and apoptosis. As the site with the highest CB 1 expression (but also some CB 2 expression), the brain may modulate motility, the sensation of pain and unpleasentness thus positively influencing the inflammatory process.
Research Findings Relating to Cannabidiol (CBD) and its Influence on Inflammatory Bowel Disease and Irritable Bowel Syndrome - by Nurse Romy -
1 Research Findings Relating to Cannabidiol (CBD) and its Influence on Inflammatory Bowel Disease and Irritable Bowel Syndrome - by Nurse Romy - This article is based upon published scientific findings.
More informationCase Report: Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy
Case Report: Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy Natasha R. Ryz, PhD*, Caroline MacCallum, MD (FRCPC Internal Medicine)**, Robert T. Brooke*
More informationCannabis for the treatment of Crohn s disease(protocol)
Cochrane Database of Systematic Reviews Cannabis for the treatment of Crohn s disease(protocol) Kafil TS, Nguyen TM, MacDonald JK, Chande N Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the
More informationThe use of cannabis, commonly referred to as marijuana, is
Therapeutic Use of Cannabis in Inflammatory Bowel Disease Waseem Ahmed, MD, and Seymour Katz, MD Dr Ahmed is an internal medicine resident at the New York University Medical Center in New York, New York.
More informationIs there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital
Is there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital Disclosures No relevant financial or relationship disclosures
More informationGetting into the weed: the endocannabinoid system of the gut-brain axis in energy homeostasis. Keith Sharkey
Getting into the weed: the endocannabinoid system of the gut-brain axis in energy homeostasis Keith Sharkey Department of Physiology & Pharmacology University of Calgary Dr. Keith Sharkey Financial Interest
More informationComplementary & Alternative Therapies in IBD
Complementary & Alternative Therapies in IBD Laurie Rosales, APRN-CNP OSU Wexner Medical Center Division of Gastroenterology, Hepatology and Nutrition Complementary & Alternative Probiotics Cannabis Fish
More informationLeaky Gut Syndrome: Cannabinoids and the Endocannabinoid System (ECS) as a therapeutic target.
Leaky Gut Syndrome: Cannabinoids and the Endocannabinoid System (ECS) as a therapeutic target. By Kyle Boyar What is Leaky Gut Syndrome and how is it diagnosed? Leaky Gut Syndrome (LGS) is an ailment characterized
More informationSCFA in gut health. Kristin Verbeke. On behalf of the Prebiotic Task Force of ILSI Europe
SCFA in gut health Kristin Verbeke Translational Research in Gastrointestinal Disorders KU Leuven On behalf of the Prebiotic Task Force of ILSI Europe Acetic acid Major anions in the large intestine Propionic
More informationCB2-mediated immunoregulation in Inflammatory Bowel Disease. David Ziring, MD Clinical Instructor, UCLA Div of Peds GI
CB2-mediated immunoregulation in Inflammatory Bowel Disease David Ziring, MD Clinical Instructor, UCLA Div of Peds GI Overview Why study cannabinoid signaling in intestinal immunoregulation? G_i2 -/- mice
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationExosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE
Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray
More informationPHYTOCANNABINOIDS AND THEIR MEDICINAL APPLICATIONS
Toll Free: 1.800.516.1504 info@vitaliset.com vitaliset.com Find us on Instagram! vitalisextractiontech PHYTOCANNABINOIDS AND THEIR MEDICINAL APPLICATIONS A recent history of prejudice against the cannabis
More informationResearch on Cannabis and PD: Is there any evidence?
Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES
More informationNaltrexone for the treatment of Crohn s disease
Naltrexone for the treatment of Crohn s disease DR. NILESH CHANDE COORDINATING EDITOR, IBD REVIEW GROUP; UNIVERSITY OF WESTERN ONTARIO, LONDON, ON CANADA Opioid receptors 3 major types kappa κ delta δ
More informationFaecal Calprotectin. Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS)
Faecal Calprotectin Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS) Reliable, Non Invasive Identification of IBD vs IBS Available from Eurofins
More informationulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236
Subject Index Actin cellular forms 48, 49 epidermal growth factor, cytoskeletal change induction in mucosal repair 22, 23 wound repair 64, 65 polyamine effects on cytoskeleton 49 51 S-Adenosylmethionine
More informationMarijuana and the Liver. Lauren Myers MMsc, PA-C
Marijuana and the Liver Lauren Myers MMsc, PA-C Disclosures 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose. 2. The planners, Atif Zaman, MD, MPH have
More informationAnti-inflammatory Cannabinoids without psycho-active side-effects
Anti-inflammatory Cannabinoids without psycho-active side-effects Opportunities for further development to a drug formulation Introduction More than 5000 years ago, the Chinese already used Cannabis for
More informationMedical Cannabis. Christine Yoshioka, NP
Medical Cannabis Christine Yoshioka, NP Objectives Brief history of Cannabis in cultures Review of the Endocanabinoid system Exogenous cannabis Medical research involving cannabis and federal restrictions
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationGenetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD
Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School
More informationCannabinoids & Pain. the state of the art the state of the science. Insights from Academic and Industry leaders. Background on. Cannabinoids and Pain
WHTE PAPER Cannabinoids & Pain the state of the art the state of the science Insights from Academic and Industry leaders Background on Cannabinoids and Pain About the Cannabinoids and Pain 2012 Symposium
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationMedical Marijuana for Pain How Does Cannabis Work on Your Body?
Medical Marijuana for Pain How Does Cannabis Work on Your Body? Jeremy Spiegel, MD Medical Director - Casco Bay Medical Westbury, Long Island, New York Intro Brief History of Cannabis Physiology of Cannabis
More information(THC) Delta9-tetrahydrocannabinol:
(THC) Delta9-tetrahydrocannabinol: Most prominent compound found in the cannabis plant found in the 1960 s. THC binds to the CB1 and CB2 receptors causing a change in the function of the cell it is binding.
More informationInvestigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationThe Scientific Side of Medical Marijuana
The Scientific Side of Medical Marijuana Ken Mackie, MD Indiana University Bloomington, IN December 3, 2009 kmackie@indiana.edu Financial disclosures NIH (NIDA) - research grants Alzheimer s Association
More informationThe National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION
The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION You are reading this pamphlet because you or someone you known
More informationMedical Cannabinoids for the Management of Chronic Noncancer Pain
Medical Cannabinoids for the Management of Chronic Noncancer Pain Dr Mark A. Ware MBBS MSc McGill University 12 June 2018 Disclosures Grants: CanniMed Consulting: CHI Inc Emmes 1 Canadian Consortium for
More informationMedical Cannabis: Cannabinoids and Immunomodulation
Medical Cannabis: Cannabinoids and Immunomodulation Sasha Noe, DO, PhD Board Certified Family Physician President, Hillsborough County Osteopathic Medical Society Board of Directors, Florida Society of
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationNutrition and IBD. IBD Talk. Presented by. Hannah Price, paediatric dietitian at RHH. Lauren Farquhar, adult dietitian at RHH
Nutrition and IBD IBD Talk Presented by Hannah Price, paediatric dietitian at RHH Hannah.price@ths.tas.gov.au Lauren Farquhar, adult dietitian at RHH Lauren.farquhar@ths.tas.gov.au Microbiota and IBD The
More informationPerilla frutescens for prevention of gastrointestinal discomfort. Dr. Sigrid Röchter 5. May 2015 Vitafoods Europe Conference Digestive Health Session
Perilla frutescens for prevention of gastrointestinal discomfort Dr. Sigrid Röchter 5. May 2015 Vitafoods Europe Conference Digestive Health Session Agenda 1. Consumer demand for gut health products 2.
More informationPatient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know?
Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Peter D.R. Higgins Director, IBD Program University of Michigan What are PROs? ClinRO Patient- Reported
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationRole of cannabinoids in gastrointestinal mucosal defense and inflammation
Role of cannabinoids in gastrointestinal mucosal defense and inflammation Klára Gyires*, Zoltán S. Zádori Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad
More informationZoektocht naar innovatieve geneesmiddelen voor de toekomst - Verslaving en ander gedrag in moleculair perspectief
Zoektocht naar innovatieve geneesmiddelen voor de toekomst - Verslaving en ander gedrag in moleculair perspectief Prof. dr. Chris Kruse Swammerdam Institute, UvA Solvay Pharmaceuticals Drug Discovery Assets
More informationFaecalibacterium prausnitzii
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA MINNESOTA ACADEMY OF PHYSICIAN ASSISTANTS MARCH 18, 2016 TOM ARNESON, MD, MPH MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program
More informationComplementary and Alternative Therapies in IBD
Complementary and Alternative Therapies in IBD Ross M. Maltz, MD August 19, 2018 IBD Education Day Objectives Define complementary/alternative medicine (CAM) What are patient s perception of CAM Definitions
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationCANNABIS AND CANCER. Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients
CANNABIS AND CANCER Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients Debra Kimless, M.D. Medical Director, ForwardGro CannMed 2017
More informationLecture: Medical Marijuana Long term effects and interac ons with common medicines Neuropharamacology of the brain with cannabis
Lecture: Medical Marijuana Long term effects and interac ons with common medicines Neuropharamacology of the brain with cannabis William Morrone, DO Robert Piccinini, DO Endocannabinoids in Disease and
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationSignal Transduction in Inflammatory Bowel Disease
E v e n t s 0 6 4 Signal Transduction in Inflammatory Bowel Disease 0 1 2 3 4 1 0 1 0 1 0 1 0 1 0 F L 2 - H e ig h t Vineeta Khare Ph.D Overview Inflammatory Bowel Diseases 1. Epidemiology, Symptoms and
More informationArticle: Min, T and Ford, AC (2016) Efficacy of mesalazine in IBS. Gut, 65 (1). pp ISSN
This is a repository copy of Efficacy of mesalazine in IBS. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/97338/ Version: Accepted Version Article: Min, T and Ford, AC (2016)
More informationTHC and cannabidiol affect CB 1 receptor function
THC and cannabidiol affect CB 1 receptor function Dr. Eileen Denovan-Wright, PhD Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada XXIX W.O. MCCORMICK ACADEMIC DAY CONFERENCE
More informationCorporate Presentation June OTCQB: VBIO
Corporate Presentation June 2018 @vitalitybio www.vitality.bio OTCQB: VBIO 2 Safe Harbor Statement This presentation and our commentary and responses to your questions may contain forward-looking statements,
More informationIBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease
IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease Inflammatory Bowel Disease Experts in Autoimmunity Inova Diagnostics offers a complete array of methods to aid in the diagnosis
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationCannabis & Hemp therapeutic solutions
Cannabis & Hemp therapeutic solutions with Our Cannabis & Hemp quality standards Thanks to their rich characterization and proprietary extraction method, our therapeutic solutions are a reference point
More informationThis is a duplicated text of a letter from GW Pharma Ltd. Contact the company for a copy of any references, attachments or enclosures.
Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers and other interested parties. Although Health
More informationDate of preparation: 06/ IBD/
Mechanisms Mechanisms of of Disease Disease: The The Science of of IBD IBD 64002 Date of preparation: 06/11 2013 IBD/2013-11-01 Table of Contents IBD Background and Disease Management Etiology and Pathophysiology
More informationObjectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access
Medical Marijuana Deb Evans, RN, MScN, CON(C), CHPCN(C) Clinical Nurse Specialist Pain and Symptom Management Team Juravinski Cancer Centre May 29, 2014 Objectives 1. Review controversy 2. Pathophysiology
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationComplementary and Alternative Medicine in Inflammatory Bowel Disease. Katherine Baldwin, MD
Complementary and Alternative Medicine in Inflammatory Bowel Disease Katherine Baldwin, MD What Is CAM? Definition: Complementary and alternative medicine is a group of diverse medical and health care
More informationwe ve got fine tuning possibilities, and that s certainly possible with modifying the enzymes that synthesize or degrade the endogenous cannabinoids
The CCIC Podcast February 24, 2015 This month: Prof. Steve Alexander Interview by Dr. Mark A. Ware www.ccic.net/podcast Introduction Hello and welcome to the CCIC Podcast. The CCIC Podcast is a series
More information17 th International Conference of the Inflammation Research Association: Wednesday AM (Day 4) September 9-13, 2012
17 th International Conference of the Inflammation Research Association: Wednesday AM (Day 4) September 9-13, 2012 The Sagamore Resort, Bolton Landing, NY, USA The following report includes highlights
More informationCannabinoids in Vet Medicine
Cannabinoids in Vet Medicine Landa L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Veterinary Medicine 61 (3), 2016: A little
More informationCannabinoids in Medicine An Option? Psychiatric Diseases
Swiss Task Force for Cannabinoids in Medicine, STCM Bern, January 22 nd, 2013 Cannabinoids in Medicine An Option? Psychiatric Diseases S S A M Dr. med. Robert Hämmig Psychiatrie & Psychotherapie FMH Präsident
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP
ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP Page 1 1. In what year did the possession and transfer of cannabis for recreational use become illegal in the United States? A. 1937 B. 1941 C. 1933 2.
More informationCannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
More informationNUTRITION, CANNABIS AND CANCER
NUTRITION, CANNABIS AND CANCER Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients Debra Kimless, M.D. Medical Director, ForwardGro The
More informationGetting Into the Weed: Potentials and Pitfalls Affecting Medical Use
Getting Into the Weed: Potentials and Pitfalls Affecting Medical Use Cydney E. McQueen, PharmD Clinical Associate Professor UMKC School of Pharmacy Objectives Describe in simple terms the endocannabinoid
More informationInnate immunity as a therapeutic target in IBD. Elke Cario Division of Gastroenterology & Hepatology University Hospital of Essen Essen, Germany
Innate immunity as a therapeutic target in IBD Elke Cario Division of Gastroenterology & Hepatology University Hospital of Essen Essen, Germany The intestinal mucosa must rapidly recognize luminal pathogens
More informationEndocannabinoids in the gastrointestinal tract
Am J Physiol Gastrointest Liver Physiol 311: G655 G666, 2016. First published August 18, 2016; doi:10.1152/ajpgi.00294.2015. Review Endocannabinoids in the gastrointestinal tract Yunna Lee, 1 * Jeongbin
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationMedical Marijuana. 1. is a plant species, variety known as hemp. 3. Tetrahydrocannabinol is an aromatic with low water solubility.
Medical Marijuana Questions from Part 1: 1. is a plant species, variety known as hemp. a. Cannabis sativa Linnaeus b. Cannabis sativa c. Cannabis indica d. Cannabis Lemark 2. The major psychoactive compound
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationmarijuana and the teen brain MARY ET BOYLE, PH. D. DEPARTMENT OF COGNITIVE SCIENCE UCSD
marijuana and the teen brain MARY ET BOYLE, PH. D. DEPARTMENT OF COGNITIVE SCIENCE UCSD in this talk what is marijuana? the brain on marijuana is the teen brain special? current research what is marijuana?
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA EPILEPSY & SEIZURES WELLNESS EXPO APRIL 16, 2016 MICHELLE LARSON, MPA MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program State
More informationCBD and Your Health.
CBD and Your Health. Cannabidiol (CBD) is a molecule found in plant species such as agricultural (or industrial) hemp, and Echinacea. CBD is one of at least 489 distinct compounds within hemp: it is clear
More informationPostoperative Ileus. UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011
Postoperative Ileus UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Hobart W. Harris, MD, MPH Introduction Pathophysiology Clinical Research Management Summary Postoperative Ileus:
More informationWeekly Prevalence of Symptoms USA vs. Colombia
THE OVERLAP BETWEEN INFLAMMATORY BOWEL DISEASE AND FUNCTIONAL GASTROINTESTINAL DISORDERS: CHALLENGES AND TREATMENT IMPLICATIONS Miguel Saps, MD Professor of Pediatrics, Ohio State University Director of
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationDevelopment of Optimum Information System for Health Management in Patients with Crohn s Disease
, pp.224-229 http://dx.doi.org/10.14257/astl.2014.53.47 Development of Optimum Information System for Health Management in Patients with Crohn s Disease Seong-Ran Lee ¹Department of Medical Information,
More informationCBD Oil: Anxiety Aid & Much More
CBD Oil: Anxiety Aid & Much More This often misunderstood hemp extract may be a health miracle for many. LISA TURNER NOV 1, 2017 betternutrition.com You ve probably heard of and wondered about CBD (cannabidiol),
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More information... SELECTED ABSTRACTS...
... SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on irritable bowel syndrome, were selected for their relevance to this supplement. A Technical Review for
More informationCANNABIS AND PAIN. Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018
CANNABIS AND PAIN Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018 FDA APPROVAL: PREGABALIN, DULOXETINE, MILNACIPRAN FOR FIBROMYALGIA PREGABALIN, DULOXETINE FOR
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationCannabinoids and Epilepsy. Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics
Cannabinoids and Epilepsy Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics Cannabinoids Cannabinoids= terpenophenolic compounds (give a scent) >80 in Cannabis sativa Cannabidiol
More informationFOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015
Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis
More informationTHE MEDITERRANEAN IS OUR INSPIRATION
THE MEDITERRANEAN IS OUR INSPIRATION NATURAL INGREDIENTS FOR NUTRACEUTICAL AND COSMETIC APPLICATIONS Azienda certificata secondo le norme ISO 9001 (n. IT255373) e ISO 13485 (n. It255838) The artichoke
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationNew potential therapeutic applications for certain phytocannabinoids revealed by pharmacological discoveries Roger Pertwee
New potential therapeutic applications for certain phytocannabinoids revealed by pharmacological discoveries Roger Pertwee UNIVERSITY OF ABERDEEN Cannabis - a unique source of phytocannabinoids (at least
More informationModulation of abdominal pain by probiotics. Anna Lyra, PhD DuPont Nutrition & Health
Modulation of abdominal pain by probiotics Anna Lyra, PhD DuPont Nutrition & Health Functional gastrointestinal (GI) wellbeing Up to 70% suffer from functional GI symptoms - ¾ do not seek medical care
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More information12/10/2009. Department of Pathology, Case Western Reserve University. Mucosal Cytokine Network in IBD
Cytokine-Mediated Inflammation in IBD Theresa T. Pizarro Department of Pathology, Case Western Reserve University Mucosal Cytokine Network in IBD Andoh, et al., 2008 1 Interleukin-1 (IL-1) Family Cytokine
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More information